Atacicept Biosimilar - Anti-BAFF and APRIL fusion protein - Research Grade
Expression system
XtenCHO
Purity
>90% by SDS-PAGE.
Buffer
0.01M PBS, pH 7.4.
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
anti-TNF- and APOL-related leukocyte expressed ligand 2, APRIL, CD256, Tumor necrosis factor ligand superfamily member 13, TNF-related death ligand 1, TALL-2, TNFSF13, ZTNF2, A proliferation-inducing ligand, TALL2, TRDL-1, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
Reference
PX-TA2002
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
Fusion - [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 - IGHG1 Fc (Fragment constant)
Description of Atacicept Biosimilar - Anti-BAFF and APRIL fusion protein - Research Grade
Introduction
The Atacicept Biosimilar – Anti-BAFF and APRIL fusion protein is a novel therapeutic antibody that has shown promising results in preclinical studies for the treatment of various autoimmune diseases. This research grade antibody is designed to target the B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key players in the development and progression of autoimmune diseases.
Structure of Atacicept Biosimilar
The Atacicept Biosimilar is a fusion protein consisting of two extracellular domains of the human TACI receptor (transmembrane activator and calcium modulator and cyclophilin ligand interactor) fused to the Fc region of a human immunoglobulin G1 (IgG1) antibody. This unique fusion design allows for high specificity and affinity towards BAFF and APRIL, making it a potent therapeutic agent.
The TACI receptor is a member of the tumor necrosis factor (TNF) receptor superfamily and is expressed on the surface of B-cells, T-cells, and dendritic cells. It plays a crucial role in regulating B-cell survival and differentiation. The Fc region of the Atacicept Biosimilar is responsible for antibody effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Mechanism of Action
The Atacicept Biosimilar works by binding to both BAFF and APRIL, preventing them from interacting with their respective receptors on B-cells. This effectively blocks the survival and differentiation signals that these cytokines provide to B-cells, leading to their depletion. This depletion of B-cells is beneficial in autoimmune diseases, where excessive B-cell activity is a major contributing factor.
In addition to B-cell depletion, the Atacicept Biosimilar also inhibits the production of autoantibodies by B-cells. This is achieved by blocking the maturation of B-cells into plasma cells, which are responsible for producing antibodies. This dual mechanism of action makes the Atacicept Biosimilar a potent and versatile therapeutic agent for a wide range of autoimmune diseases.
Applications of Atacicept Biosimilar
The Atacicept Biosimilar has shown promising results in preclinical studies for the treatment of various autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. It has also shown potential in the treatment of B-cell malignancies, such as multiple myeloma and chronic lymphocytic leukemia.
Furthermore, the Atacicept Biosimilar has the potential to be used in combination with other therapies for a synergistic effect. For example, it can be used in combination with B-cell depleting agents, such as rituximab, to achieve a more comprehensive depletion of B-cells and improve treatment outcomes.
Conclusion
The Atacicept Biosimilar – Anti-BAFF and APRIL fusion protein is a novel therapeutic antibody with a unique fusion design that allows for high specificity and affinity towards BAFF and APRIL. Its dual mechanism of action of B-cell depletion and inhibition of autoantibody production makes it a promising candidate for the treatment of various autoimmune diseases. With further research and clinical trials, the Atacicept Biosimilar has the potential to become a valuable addition to the arsenal of therapies available for autoimmune diseases.
Reviews
There are no reviews yet.